ISSUE 1362
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved Fortesta (Endo), a topical gel, for testosterone replacement therapy in adult males with hypogonadism. It is classified as a Schedule III controlled substance. Table 1 lists some available testosterone products, including 2 other gels.
HYPOGONADISM — Failure of the testes to produce adequate amounts of testosterone can lead to loss of energy, decreased libido, erectile dysfunction, decreased axillary and pubic hair, loss of muscle mass, anemia and osteoporosis.1 Testosterone serum concentrations are difficult to measure and may require 2 or more determinations. Levels decrease with age, falling by about 1-2% per year after the age of 40.2 The normal range (usually ≥300 ng/dL) is based on serum concentrations in young men. Older men with signs and symptoms of hypogonadism may have levels
... moreWould you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1362b
Electronic, downloadable article - $45